6 assets in Extramammary Paget Disease

Therapeutic assets addressing Extramammary Paget Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Extramammary Paget Disease	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Extramammary Paget Disease	National Cancer Institute (NCI)	P2	CCC (53)
Ivocizumab Extramammary Paget Disease	Fudan University	P2	CCC (53)
Nivolumab Extramammary Paget Disease	National Cancer Institute (NCI)	P2	CCC (53)
mq719 Extramammary Paget Disease	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Pembrolizumab Extramammary Paget Disease	Memorial Sloan Kettering Cancer Center	P1	CC (43)